Abstracts tagged "organ and belimumab"

Abstract Number: 858 • 2019 ACR/ARP Annual Meeting
Adverse Events of Special Interest, SLE Medication Utilization, Hospitalizations, and Organ Damage: Results from a Phase 4, Randomized, Double-Blind, Placebo-Controlled, 52-week Study of Belimumab in Adults with Active, Autoantibody-Positive SLE
Saira Sheikh¹, Morton Scheinberg ², Cheng-Chung Wei ³, Dana Tegzova ⁴, William Stohl ⁵, Ricardo Acayaba de Toledo ⁶, Tamara Mucenic ⁷, Mauricio Abello Banfi ⁸, Kathleen Maksimowicz-McKinnon ⁹, Carlos Abud-Mendoza ¹⁰, Sandra Navarra ¹¹, Mercedes Garcia ¹², Ignacio Garcia-De La Torre ¹³, Josep Ordi Ros ¹⁴, Roger Abramino Levy ¹⁵, Damon L Bass ¹⁵, Jorge Ross Terrés ¹⁶, Raj Punwaney ¹⁶, Julia Harris ¹⁷, Alireza Nami ¹⁸, Amy Pierce ¹⁹, Kevin Thorneloe ²⁰, Beulah Ji ¹⁷ and David Roth ¹⁶, ¹University of North Carolina, Chapel Hill, NC, ²Centro de Pesquisas Clinicas do Hospital Abreu Sodré, São Paulo, Brazil, ³Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ⁴Institute of Rheumatology, Prague, Czech Republic, ⁵University of Southern California Keck School of Medicine, Los Angeles, CA, ⁶Faculdade de Medicina de São José do Rio Preto, São Paulo, Brazil, ⁷Hospital Moinhos Angeles de Vento, Porto Alegre, Brazil, ⁸Centro Integral de Reumatología del Caribe, Barranquilla, Colombia, ⁹Henry Ford Hospital, Wayne State University, Detroit, MI, ¹⁰Hospital Central “Dr Ignacio Morones Prieto”, Unidad Regional de Reumatologia y Osteoporosis, Hospital Central and Facultad de Medicina de la Universidad Autónoma de San Luis Potosí, San Luis Potosi, Mexico, ¹¹University of Santo Tomas Hospital, Manila, Philippines, ¹²Hospital San Martín, La Plata, Argentina, ¹³Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Jalisco, Mexico, ¹⁴Hospital Vall d'Hebron, Barcelona, Spain, ¹⁵GlaxoSmithKline, Collegeville, PA, ¹⁶GSK, Collegeville, PA, ¹⁷GSK, Uxbridge, Middlesex, United Kingdom, ¹⁸Joint Muscle Medical Care and Research Institute, Charlotte, NC, ¹⁹ViiV Healthcare, Research Triangle Park, NC, ²⁰GSK, Collegeville, NC
Background/Purpose: Belimumab (BEL), approved in active, autoantibody-positive SLE, has demonstrated a positive efficacy/safety profile while suggesting potential for steroid sparing and reduced organ damage accrual.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].